NEW YORK & BURLINGTON, Mass. / Dec 16, 2024 / Business Wire / Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”), a digital health company transforming care with handheld, whole-body ultrasound and intuitive software, today announced that it will participate at the 43rd Annual J.P. Morgan Healthcare Conference taking place January 13-16, 2025 at the Westin St. Francis in San Francisco, California. Joseph DeVivo, President, Chief Executive Officer & Chairman and Heather Getz, Executive Vice President & Chief Financial and Operations Officer, will present on Thursday, January 16, 2025, at 7:30 AM PST.
A webcast of the presentation will be posted on the Events & Presentations section of the Butterfly investor website, and available for replay until February 15, 2025.
To schedule a meeting with Mr. DeVivo and Ms. Getz, please reach out to the Company directly via the contacts below or request a one-on-one through your J.P. Morgan representative.
About Butterfly Network
Founded by Dr. Jonathan Rothberg in 2011, Butterfly Network is a digital health company with a mission to democratize medical imaging by making high-quality ultrasound affordable, easy-to-use, globally accessible, and intelligently connected, including for the 4.7 billion people around the world lacking access to ultrasound. Butterfly created the world's first handheld single-probe, whole-body ultrasound system using semiconductor technology, Butterfly iQ. The company has continued to innovate, leveraging the benefits of Moore’s Law, to launch its second generation Butterfly iQ+ in 2020, and third generation iQ3 in 2024 – each with increased processing power and performance enhancements. The disruptive technology has been recognized by TIME’s Best Inventions, Fast Company’s World Changing Ideas, CNBC Disruptor 50, and MedTech Breakthrough Awards, among other accolades. With its proprietary Ultrasound-on-Chip™ technology, intelligent software, and educational offerings, Butterfly is paving the way to mass adoption of ultrasound for earlier detection and remote management of health conditions around the world. Butterfly devices are commercially available to trained healthcare practitioners in areas including, but not limited to, parts of Africa, Asia, Australia, Europe, the Middle East, North America and South America; to learn more about available countries, visit: butterflynetwork.com/choose-your-country.
Last Trade: | US$2.34 |
Daily Change: | -0.01 -0.43 |
Daily Volume: | 2,111,451 |
Market Cap: | US$436.740M |
February 28, 2025 January 29, 2025 January 13, 2025 January 08, 2025 November 01, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load